ATE445413T1 - USE OF STRAINS OF PARAPOXVIRUS OVIS AGAINST ORGAN FIBROSIS - Google Patents

USE OF STRAINS OF PARAPOXVIRUS OVIS AGAINST ORGAN FIBROSIS

Info

Publication number
ATE445413T1
ATE445413T1 AT01965110T AT01965110T ATE445413T1 AT E445413 T1 ATE445413 T1 AT E445413T1 AT 01965110 T AT01965110 T AT 01965110T AT 01965110 T AT01965110 T AT 01965110T AT E445413 T1 ATE445413 T1 AT E445413T1
Authority
AT
Austria
Prior art keywords
strains
organ fibrosis
fibrosis
parapoxvirus ovis
orf
Prior art date
Application number
AT01965110T
Other languages
German (de)
Inventor
Claudia Hirth-Dietrich
Tobias Schlapp
Angela Siegling
Andreas Knorr
Olaf Weber
Gudrun Theiss
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Priority claimed from PCT/EP2001/007978 external-priority patent/WO2002004019A2/en
Application granted granted Critical
Publication of ATE445413T1 publication Critical patent/ATE445413T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24261—Methods of inactivation or attenuation
    • C12N2710/24264—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Addiction (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide a medicament having a preventive or curative effect on organ fibrosis in humans.SOLUTION: The medicament shows the effect to a common final path to all diseases connected to fibrosis, using the fact that a preparation of parapoxviruses, obtained from the strains D 1701, orf-11, Greek orf strain 176, Greek orf strain 155, and the New Zealand (NZ) strains inhibit transformation of hepatic stellate cells into collagen producing-myofibroblast type.
AT01965110T 2000-07-11 2001-07-11 USE OF STRAINS OF PARAPOXVIRUS OVIS AGAINST ORGAN FIBROSIS ATE445413T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10033581 2000-07-11
DE10122233A DE10122233A1 (en) 2000-07-11 2001-05-08 Use of strains of the Parapoxvirus ovis against organ fibrosis
PCT/EP2001/007978 WO2002004019A2 (en) 2000-07-11 2001-07-11 Use of strains of the parapox ovis virus against organ fibrosis

Publications (1)

Publication Number Publication Date
ATE445413T1 true ATE445413T1 (en) 2009-10-15

Family

ID=7648485

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01965110T ATE445413T1 (en) 2000-07-11 2001-07-11 USE OF STRAINS OF PARAPOXVIRUS OVIS AGAINST ORGAN FIBROSIS

Country Status (14)

Country Link
JP (2) JP5587950B2 (en)
KR (1) KR100845643B1 (en)
CN (1) CN101444539B (en)
AT (1) ATE445413T1 (en)
BR (1) BRPI0112411B8 (en)
DE (2) DE10122233A1 (en)
DK (1) DK1303302T3 (en)
DO (1) DOP2001000210A (en)
EC (1) ECSP034420A (en)
ES (1) ES2332355T3 (en)
PE (1) PE20020218A1 (en)
PT (1) PT1303302E (en)
SV (1) SV2002000527A (en)
ZA (1) ZA200300276B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102015111756A1 (en) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Recombinant Orf virus vector
EA201891848A1 (en) * 2016-02-16 2019-02-28 Осака Юниверсити PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF FIBROSIS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405841C1 (en) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotent non-specific immunity inducers based on combinations of poxvirus components, processes for their preparation and their use as pharmaceuticals
PT885013E (en) * 1996-04-15 2002-01-30 Anton Mayr Prof Dr Med Vet Dr USE OF MULTI-POTENTIAL INDUCTORS BASED ON POXVIRUSES OR PARAPOXVIRUS ATENUATED AND NOT IMMUNOGENIC FOR THE MANUFACTURE OF MEDICINES

Also Published As

Publication number Publication date
BRPI0112411B8 (en) 2021-05-25
SV2002000527A (en) 2002-10-24
DK1303302T3 (en) 2010-02-08
ES2332355T3 (en) 2010-02-03
JP2014196329A (en) 2014-10-16
KR20030019562A (en) 2003-03-06
KR100845643B1 (en) 2008-07-10
ZA200300276B (en) 2004-04-13
BRPI0112411B1 (en) 2018-02-27
BR0112411A (en) 2003-05-27
JP5587950B2 (en) 2014-09-10
PE20020218A1 (en) 2002-05-19
DE10122233A1 (en) 2002-01-24
CN101444539A (en) 2009-06-03
ECSP034420A (en) 2003-03-10
PT1303302E (en) 2009-11-11
DOP2001000210A (en) 2002-12-15
JP5950964B2 (en) 2016-07-13
JP2012214492A (en) 2012-11-08
CN101444539B (en) 2016-07-06
DE50115181D1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
FI20011851A (en) Fluoxetine or its acid addition salt dispersible tablet
ATE514418T1 (en) RAPIDLY DISRUPTING SOLID DOSAGE FORMS WITH NON-FRUABLE CONSISTENCY AND PULLULAN
NO330953B1 (en) Use of ranolazine for the preparation of a pharmaceutical composition for the treatment of arrhythmias
ES2195866T3 (en) MULTIUS ACID COMPOSITIONS.
WO2002083879A3 (en) Immunotherapy based on dendritic cells
NO20004282L (en) Matrix protein preparations for wound healing
DK0942741T3 (en) Lectin preparations and uses thereof
BR0014905A (en) Anti-virus fabric product and process to produce the same
ATE445413T1 (en) USE OF STRAINS OF PARAPOXVIRUS OVIS AGAINST ORGAN FIBROSIS
CY1105205T1 (en) USE OF DOCOSAEXANOIC ACID AS AN ACTIVE SUBSTANCE FOR THE TREATMENT OF LIPODYSTROPHIA
BR0314804A (en) Modified Release Dosage Form
NO20030081L (en) Use of parapoxvirus strains against organ fibrosis
Akbar et al. Quercus infectoria G. Olivier (Fagaceae) (Syns.: Q. boissieri Reut.; Q. carpinea Kotschy ex A. DC; Q. grosseserrata Kotschy ex Wenz.; Q. puberula O. Schwarz; Q. thirkeana K. Koch)
SE9902268D0 (en) Pharmaceutically active compounds
SE0101328D0 (en) Therapeutic treatment
Nakashima et al. Mothproofing efficacy of wool-yarn treated with several kinds of medical herb against to cloth moth, Tinea Pellionella (L.)
Vazquez How low can you go
Verheugt Differential dose effect of aspirin in the primary prevention of myocardial infarction
UA38162A (en) Method for preventing thromboembolism in patients with atrial fibrillation
ITCN20050012A1 (en) THE SMOKE OF HEALTH - PROCEDURE PATENT (ART. 67 LEGISLATIVE DECREE 30/2005) TO ABSORBATE THROUGH THE SMOKE THE ACTIVE PRINCIPLES OF SOME OFFICINAL, AROMATIC, MEDICINAL PLANTS AND VEGETABLES, APPROPRIately DRIED OR SMOOTHED OR FERMENTED OR TANNED OR D
RU2000124123A (en) METHOD FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
CY1115214T1 (en) USE OF RANOLAZINE FOR THE PREPARATION OF A MEDICINE FOR TREATMENT OF NUMBERS
BG106211U (en) Preparation for pediculus humanis control
BRPI0705224A2 (en) use of pau ferro extract (caesalpinia ferrea mart.) in cosmetic and pharmaceutical formulations as a depigmenting / skin whitening agent
GEP20032945B (en) Medicinal Preparations